Patents Assigned to Boehringer Ingelheim International GmbH
  • Patent number: 10385134
    Abstract: The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: August 20, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Sanjaya Singh, Alisa K. Waterman, Erik Depla, Toon Laeremans, Diane Van Hoorick, Cedric Jozef Néotère Ververken
  • Patent number: 10377828
    Abstract: The present invention relates to an insulin-like growth factor (IGF) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (BPH), prostate cancer, and particularly CRPC, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: August 13, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Paul Adam, Katrin Friedbichler
  • Patent number: 10377804
    Abstract: The present invention relates to anti-BAFF antibody molecules, including novel humanized anti-BAFF antibodies, therapeutic and diagnostic methods and compositions for using the same.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: August 13, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Keith A. Canada, Michael Dziegelewski, Philip Nicholas Gorman, Pankaj Gupta, Ashraf Khalil, John J. Miglietta, Amy Marie Nicoletti, Qi Pan, David Presky, Sanjaya Singh, Tao Wu, Haiguang Xiao
  • Publication number: 20190231766
    Abstract: The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof.
    Type: Application
    Filed: April 10, 2019
    Publication date: August 1, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Ulrich BRAUNS, Norbert HAUEL, Peter SIEGER
  • Patent number: 10363559
    Abstract: The invention relates to an apparatus for separating blood and at the same time an apparatus (1) for absorbing blood (19) and separating components such as blood plasma, as a sample liquid (2), having a feed device (13) for receiving the blood (2), a separating device (15) for separating blood components as the sample liquid (2), a channel (3) which takes up the sample liquid (2) preferably exclusively by capillary forces and a fill device for filling the channel (3) with sample liquid (2) in an inlet or feed region (18) of the channel (3), wherein the separating device (15), particularly a membrane, is domed, more particularly convexly shaped and projects with the apex of the convex shape into the filling device in the direction of filling.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: July 30, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Gert Blankenstein, Holger Bartos, Ralf-Peter Peters, Christian Schoen
  • Patent number: 10336729
    Abstract: The invention relates to new benzonitrile derivatives of the formula (I) wherein R1 to R3 and A are as defined in the description and Claims, to their medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: July 2, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Frank Himmelsbach, Andreas Blum, Stefan Peters
  • Patent number: 10328074
    Abstract: Method for treating AML and MM by administration of a compound of the formula (I) wherein the groups R1 to R3 have the meanings given in the specification.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: June 25, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Davide Gianni, Christian Smethurst
  • Patent number: 10329292
    Abstract: The present invention relates to substituted xanthine derivatives, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment of conditions having an association with TRPC5 containing ion channels.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: June 25, 2019
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, Inc.
    Inventors: Kai Gerlach, Christian Eickmeier, Achim Sauer, Stefan Just, Bertrand L. Chenard
  • Publication number: 20190177420
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same for treating and/or preventing lupus nephritis.
    Type: Application
    Filed: July 18, 2018
    Publication date: June 13, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Scott Ronald Brodeur, Thomas B. Freeman, Gerald Henery Nabozny, Meera Ramanujam, Paul Scholl, Juergen Steffgen
  • Publication number: 20190169301
    Abstract: The present invention relates to new humanized antagonistic anti-CD40 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: July 10, 2018
    Publication date: June 6, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Scott Ronald Brodeur, Keith Canada, Tobias Litzenburger, Sanjaya Singh
  • Patent number: 10308667
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: June 4, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Cédrickx Godbout, Thomas Trieselmann, Viktor Vintonyak
  • Patent number: 10308414
    Abstract: Methods and systems for calculating a suitability indicator which corresponds to a suitability of a packaging system for packaging a substance, where a stability indicator which corresponds to a stability of the substance or of a component of the substance is determined as a function of at least one ambient condition, preferably the relative humidity and/or temperature of the environment of the substance, and the suitability indicator is calculated with at least one parameter relating to the ambient condition and with the stability indicator of the substance.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: June 4, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Eduard Balthes
  • Patent number: 10307402
    Abstract: The present invention relates to compounds of general formula I, wherein the group R1, X and Y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: June 4, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Gottschling, Joerg P. Hehn, Christoph Hoenke, Elke Langkopf
  • Patent number: 10301313
    Abstract: The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: May 28, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Peter Sieger, Dirk Kemmer, Peter Kohlbauer, Thomas Nicola, Martin Renz
  • Publication number: 20190144534
    Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.
    Type: Application
    Filed: January 25, 2019
    Publication date: May 16, 2019
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Rachel Rebecca Barrett, Keith A. Canada, Katrina Mary Catron, Robert Copenhaver, Lee Edward Frego, Ernest Lee Raymond, Sanjaya Singh, Xiangyang Zhu
  • Patent number: 10287318
    Abstract: The invention relates to novel peptides, polypeptides or proteins which bind specifically to brain cells and/or to the spinal cord. The peptides, polypeptides, or proteins can be components of a viral capsid and can be used to lead a recombinant viral vector selectively to the brain and/or spinal cord after systemic administration to a subject and to ensure tissue-specific expression of one or more transgenes there. The invention also relates to a recombinant viral vector, preferably an AAV vector, which comprises a capsid containing at least one of the claimed peptides, polypeptides, or proteins and which comprises at least one transgene packaged in the capsid. Said viral vector can be used, in particular for the therapeutic treatment of a disease or disorder of the brain and/or spinal cord. The invention further relates to cells and pharmaceutical compositions that comprise the viral vector according to the invention.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: May 14, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jakob Körbelin, Stefan Michelfelder, Martin Trepel
  • Patent number: 10280133
    Abstract: The present invention relates to a process for the preparation of 4-aminobenzoamidine (4-AMBA) salts of general formula (I) preferably the salts thereof with hydrochloric or hydrobromic acid, particularly preferred the dichloride salt.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: May 7, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Weitong Dong, Christian Wolfgang Hemp, Xiangle Jin, Jun Lu, Ulrich Scholz, Shengmin Su, Wei Xu, Jinsong Yang
  • Patent number: 10280231
    Abstract: The disclosure relates to compounds specific for IL23A and BAFF, compositions comprising the compounds, and methods of use thereof. Nucleic acids, cells, and methods of production related to the compounds and compositions are also disclosed.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: May 7, 2019
    Assignees: Boehringer Ingelheim International GmbH, MacroGenics, Inc.
    Inventors: Sanjaya Singh, Qi Pan, Rachel Rebecca Barrett, Leslie S. Johnson, Pankaj Gupta, Sarah Low, Haixia Wu
  • Patent number: 10272215
    Abstract: An inhalation training device and inhalation training system for practicing of an inhalation process of a patient. The inhalation training device has a that is housing attachable to and detachable from a mouthpiece of an inhaler designed to provide a drug to the patient and a microphone adapted to measure the airflow occurring in the mouthpiece of the inhaler during an inhalation process of the patient. The inhalation training system includes the inhalation training device, an inhaler and an electronic device configured for evaluation of a signal received from the inhalation training device and for visual and/or audio feedback to the patient.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: April 30, 2019
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Patricia Adams, Marion Frank, Herbert Wachtel
  • Patent number: RE47493
    Abstract: This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: July 9, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christian Gnamm, Thorsten Oost, Stefan Peters, Klaus Rudolf